<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10215">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00682786</url>
  </required_header>
  <id_info>
    <org_study_id>02-0561</org_study_id>
    <nct_id>NCT00682786</nct_id>
  </id_info>
  <brief_title>Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma</brief_title>
  <official_title>Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine if genotype-directed neoadjuvant chemoradiation, using information from the
      thymidylate synthase promoter polymorphism, result in a greater degree of tumor downstaging
      in high risk patients compared to historical controls.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rate of Tumor Downstaging Compared With Historical Controls.</measure>
    <time_frame>1 year after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tumor downstaging (DS) is defined as a decrease in the T stage of the primary tumor by at least 1.
Historical studies demonstrate a DS rate of 45%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rates</measure>
    <time_frame>1 year after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complete tumor response is defined as the absence of any viable tumor in the rectum (ypT0).
Pathologic complete response (pCR) is defined as the absence of any viable tumor in the rectum or in the perirectal lymph nodes (ypT0N0).
pCR rate of historical controls is 8%-14%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Define Patient Quality of Life Prior to and Following Neoadjuvant Chemoradiation.</measure>
    <time_frame>Prior to start of study treatment and 3-6 weeks post completion of radiation therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>The questionnaire is encouraged but not required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine Patient Fears and Expectations of Pharmacogenetics.</measure>
    <time_frame>Prior to start of study treatment and 3-6 weeks post completion of radiation therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>The questionnaire is encouraged but not required.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Rectal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Good Risk (Thymidylate Synthase (TYMS)*2/*2, *2/*3, *2/*4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Poor Risk (Thymidylate Synthase (TYMS)*3/*3, *3/*4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Irinotecan 50 mg/m2 IV weekly for 5 doses.
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5FU</intervention_name>
    <arm_group_label>Good Risk (Thymidylate Synthase (TYMS)*2/*2, *2/*3, *2/*4)</arm_group_label>
    <arm_group_label>Poor Risk (Thymidylate Synthase (TYMS)*3/*3, *3/*4)</arm_group_label>
    <other_name>Fluorouracil</other_name>
    <other_name>5-fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <arm_group_label>Good Risk (Thymidylate Synthase (TYMS)*2/*2, *2/*3, *2/*4)</arm_group_label>
    <arm_group_label>Poor Risk (Thymidylate Synthase (TYMS)*3/*3, *3/*4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery of resectable lesions</intervention_name>
    <arm_group_label>Good Risk (Thymidylate Synthase (TYMS)*2/*2, *2/*3, *2/*4)</arm_group_label>
    <arm_group_label>Poor Risk (Thymidylate Synthase (TYMS)*3/*3, *3/*4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>Poor Risk (Thymidylate Synthase (TYMS)*3/*3, *3/*4)</arm_group_label>
    <other_name>Camptosar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven adenocarcinoma of the rectum

          -  Lesion evaluated by surgeon and found to be resectable

          -  Stage T3 or T4 disease on radiography or ultrasound

          -  Karnofsky Performance Status at &gt;60

          -  Laboratory criteria:

               -  Absolute neutrophil count &gt;= 1.5 K

               -  Platelets &gt;= 100 K

               -  Total Bilirubin &lt;= 2.0;

               -  SGOT and Alkaline Phosphatase &lt;= 2 x upper limit of normal

               -  Creatinine &lt; 2.0

          -  Informed consent signed

          -  Patients with distant metastatic disease will be eligible if they satisfy all other
             conditions.

        Exclusion Criteria:

          -  Pregnant women, children &lt; 18 years, or patients unable to give informed consent

          -  Patients with a past history of pelvic radiotherapy.

          -  Patients with prior malignancy in the past 5 years except: skin cancer or in-situ
             cervical cancer. However, patients with synchronous adenocarcinomas are eligible
             provided either (a) the synchronous adenocarcinoma was in a removed pedunculated
             polyp and did not invade the stalk or (b) the synchronous adenocarcinoma was in a
             removed polyp that lay within the surgical field (extent of resection would not be
             changed) or (c) the synchronous adenocarcinoma is smaller than the index rectal
             cancer and lies completely within the radiation field (clinically favorable second
             lesion and the extend of radiation and surgery would not be changed).

          -  Patients with known allergy to 5-fluorouracil or irinotecan
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Tan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>September 2014</verification_date>
  <lastchanged_date>September 5, 2014</lastchanged_date>
  <firstreceived_date>April 11, 2008</firstreceived_date>
  <firstreceived_results_date>July 14, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rectal</keyword>
  <keyword>rectum</keyword>
  <keyword>cancer</keyword>
  <keyword>carcinoma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment to the study opened on 10/07/2002 and the study closed to enrollment on 10/23/2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Good Risk (Thymidylate Synthase (TYMS)*2/*2, *2/*3, *2/*4)</title>
          <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
        </group>
        <group group_id="P2">
          <title>Poor Risk (Thymidylate Synthase (TYMS)*3/*3, *3/*4)</title>
          <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Irinotecan 50 mg/m2 IV weekly for 5 doses.
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not receive irinotecan</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Good Risk (TYMS*2/*2, *2/*3, *2/*4)</title>
          <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
        </group>
        <group group_id="B2">
          <title>Poor Risk (TYMS*3/*3, *3/*4)</title>
          <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Irinotecan 50 mg/m2 IV weekly for 5 doses.
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="98"/>
                <measurement group_id="B2" value="37"/>
                <measurement group_id="B3" value="135"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="55" lower_limit="32" upper_limit="85"/>
                <measurement group_id="B2" value="59" lower_limit="26" upper_limit="77"/>
                <measurement group_id="B3" value="56" lower_limit="26" upper_limit="85"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="69"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="93"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="42"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="86"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="115"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="18"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Hispanic</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="98"/>
                <measurement group_id="B2" value="37"/>
                <measurement group_id="B3" value="135"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Thymidylate Synthase Enhancer Region (TSER) genotype</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>*2/*2</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="26"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>*2/*3</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="71"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="71"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>*2/*4</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>*3/*3</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="35"/>
                <measurement group_id="B3" value="35"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>*3/*4</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Performance status</title>
          <description>Eastern Cooperative Oncology Group (ECOG) Performance Status Grade 0 Fully active able to carry on all predisease performance without restriction
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (light house work/office work)
Ambulatory, capable of all selfcare but unable to carry out any work activities. Up &amp; about more than 50% of waking hours
Capable of limited selfcare, confined to bed/chair more than 50% of waking hours
Completely disabled. Cannot carry on selfcare. Totally confined to bed/chair
Dead</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>0</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="63"/>
                <measurement group_id="B2" value="26"/>
                <measurement group_id="B3" value="89"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>1</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="45"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>2</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Baseline Stage</title>
          <description>T describes how far the primary tumor has grown into the wall of the intestine and whether it has grown into nearby areas.
N describes the extent of spread to nearby lymph nodes.
M indicates whether the cancer has spread to other organs of the body.
Numbers or letters appear after T, N, and M to provide more details about each of these factors. The numbers 0 through 4 indicate increasing severity. The letter X means &quot;cannot be assessed because the information is not available.&quot;</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Stage IIA (T3, N0, M0)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="34"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Stage IIB (T4, N0, M0)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Stage IIIA (T1-2, N1, M0)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Stage IIIB (T3-4, N1, M0)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="53"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="72"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Stage IIIC (T-any, N2, M0)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Stage IV (T-any, N-any, M1)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="19"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Baseline clinical T stage</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>T1-2</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>T3</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="77"/>
                <measurement group_id="B2" value="32"/>
                <measurement group_id="B3" value="109"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>T4</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="24"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Baseline clinical N stage</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>N0</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="41"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>N1</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="64"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="86"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>N2</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Baseline clinical M stage</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>M0</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="84"/>
                <measurement group_id="B2" value="32"/>
                <measurement group_id="B3" value="116"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>M1</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="19"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Clinical staging modality</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Endoscopic ultrasound</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
                <measurement group_id="B2" value="21"/>
                <measurement group_id="B3" value="81"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>CT Scan +/- PET Scan</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="28"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>MRI</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="26"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Tumor distance from anal verge (cm)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;5</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="45"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>5-10</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="57"/>
                <measurement group_id="B2" value="21"/>
                <measurement group_id="B3" value="78"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;10</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Tumor grade</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Well differentiated</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="12"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Moderately differentiated</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="68"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="93"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Poorly differentiated</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="24"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Tumor Downstaging Compared With Historical Controls.</title>
        <description>Tumor downstaging (DS) is defined as a decrease in the T stage of the primary tumor by at least 1.
Historical studies demonstrate a DS rate of 45%.</description>
        <time_frame>1 year after enrollment</time_frame>
        <safety_issue>No</safety_issue>
        <population>8 not evaluable in Good Risk arm-(1)death before surgery (1)clinical CR w/o surgery (1)refused surgery (2)not resectable (2)withdrew consent (1)delayed surgery and given FOLFOX
6 not evaluable in Poor Risk arm-(1) death prior to surgery (1)clinical CR no surgery (1)refused surgery (2)withdrew consent (1)not given irinotecan by treating physician</population>
        <group_list>
          <group group_id="O1">
            <title>Good Risk (TYMS*2/*2, *2/*3, *2/*4)</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
          <group group_id="O2">
            <title>Poor Risk (TYMS*3/*3, *3/*4)</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Irinotecan 50 mg/m2 IV weekly for 5 doses.
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="90"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Rate of Tumor Downstaging Compared With Historical Controls.</title>
            <description>Tumor downstaging (DS) is defined as a decrease in the T stage of the primary tumor by at least 1.
Historical studies demonstrate a DS rate of 45%.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="64.4" lower_limit="54.1" upper_limit="74.6"/>
                  <measurement group_id="O2" value="64.5" lower_limit="43.7" upper_limit="78.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Response Rates</title>
        <description>Complete tumor response is defined as the absence of any viable tumor in the rectum (ypT0).
Pathologic complete response (pCR) is defined as the absence of any viable tumor in the rectum or in the perirectal lymph nodes (ypT0N0).
pCR rate of historical controls is 8%-14%.</description>
        <time_frame>1 year after enrollment</time_frame>
        <safety_issue>No</safety_issue>
        <population>8 not evaluable in Good Risk arm-(1)death before surgery (1)clinical CR w/o surgery (1)refused surgery (2)not resectable (2)withdrew consent (1)delayed surgery and given FOLFOX
6 not evaluable in Poor Risk arm-(1) death prior to surgery (1)clinical CR no surgery (1)refused surgery (2)withdrew consent (1)not given irinotecan by treating physician</population>
        <group_list>
          <group group_id="O1">
            <title>Good Risk (TYMS*2/*2, *2/*3, *2/*4)</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
          <group group_id="O2">
            <title>Poor Risk (TYMS*3/*3, *3/*4)</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Irinotecan 50 mg/m2 IV weekly for 5 doses.
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="90"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Complete Response Rates</title>
            <description>Complete tumor response is defined as the absence of any viable tumor in the rectum (ypT0).
Pathologic complete response (pCR) is defined as the absence of any viable tumor in the rectum or in the perirectal lymph nodes (ypT0N0).
pCR rate of historical controls is 8%-14%.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>ypT0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="41.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>pCR</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18.9"/>
                  <measurement group_id="O2" value="35.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Define Patient Quality of Life Prior to and Following Neoadjuvant Chemoradiation.</title>
        <description>The questionnaire is encouraged but not required.</description>
        <time_frame>Prior to start of study treatment and 3-6 weeks post completion of radiation therapy</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine Patient Fears and Expectations of Pharmacogenetics.</title>
        <description>The questionnaire is encouraged but not required.</description>
        <time_frame>Prior to start of study treatment and 3-6 weeks post completion of radiation therapy</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Toxicities by Genotype Group (Good Risk Versus Poor Risk)</title>
        <description>Grade 3 to 4 toxicities related to treatment and surgery using CTC Version 2.0.</description>
        <time_frame>First day of treatment through 30 days after completion of surgery</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Two of the patients in the Good Risk arm withdrew consent and are not included. Two of the patients in the Poor Risk arm withdrew consent and are not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Good Risk (TYMS*2/*2, *2/*3, *2/*4)</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
          <group group_id="O2">
            <title>Poor Risk (TYMS*3/*3, *3/*4)</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Irinotecan 50 mg/m2 IV weekly for 5 doses.
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="96"/>
                  <measurement group_id="O2" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Toxicities by Genotype Group (Good Risk Versus Poor Risk)</title>
            <description>Grade 3 to 4 toxicities related to treatment and surgery using CTC Version 2.0.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Nausea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dehydration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mucositis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GI bleed</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ileitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Enteritis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dyspnea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Neutropenia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anemia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Perforation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pelvic abscess</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PPE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Crohn's flare</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Syncope</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rash</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Atrial fibrillation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Small bowel obstruction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Overall Survival</title>
        <description>Analyzed using Kaplan-Meier Models.</description>
        <time_frame>1 year, 2 years, and 3 years</time_frame>
        <safety_issue>No</safety_issue>
        <population>Two of the patients in the Good Risk arm withdrew consent and are not included. Two of the patients in the Poor Risk arm withdrew consent and are not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Good Risk (TYMS*2/*2, *2/*3, *2/*4)</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
          <group group_id="O2">
            <title>Poor Risk (TYMS*3/*3, *3/*4)</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Irinotecan 50 mg/m2 IV weekly for 5 doses.
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="96"/>
                  <measurement group_id="O2" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Overall Survival</title>
            <description>Analyzed using Kaplan-Meier Models.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>1 year</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="96.9"/>
                  <measurement group_id="O2" value="94.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>2 years</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="80.6"/>
                  <measurement group_id="O2" value="94.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 years</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="78.2"/>
                  <measurement group_id="O2" value="83.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Relapse-free Survival</title>
        <description>Analyzed using Kaplan-Meier Models.</description>
        <time_frame>1 year, 2 years, and 3 years</time_frame>
        <safety_issue>No</safety_issue>
        <population>14 patients in the Good Risk arm had metastatic rectal cancer at time of enrollment are not included in this analyses.
3 patients in the Poor Risk arm had metastatic rectal disease before surgery and are included in this analyses.
2 of the patients in the Good Risk arm and Poork Risk arm withdrew consent and are not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Good Risk (TYMS*2/*2, *2/*3, *2/*4)</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
          <group group_id="O2">
            <title>Poor Risk (TYMS*3/*3, *3/*4)</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Irinotecan 50 mg/m2 IV weekly for 5 doses.
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="82"/>
                  <measurement group_id="O2" value="32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Relapse-free Survival</title>
            <description>Analyzed using Kaplan-Meier Models.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>1 year</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="85.2"/>
                  <measurement group_id="O2" value="87.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>2 years</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="78.3"/>
                  <measurement group_id="O2" value="80.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 years</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="73.4"/>
                  <measurement group_id="O2" value="72.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Associations Between MTHFR Genotypes and Grade 3-4 Diarrhea and/or Mucositis (Good Risk Group)</title>
        <description>Genomic DNA was isolated from whole blood using the Puregene DNA isolation kit.
MTHFR gene = methylenetetrahydrofolate reductase (NAD(P)H)</description>
        <time_frame>First day of treatment through 30 days after completion of surgery</time_frame>
        <safety_issue>No</safety_issue>
        <population>2 of the patients in the Good Risk arm withdrew consent and are not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Without Grade 3-4 Diarrhea and/or Mucositis</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
          <group group_id="O2">
            <title>With Grade 3-4 Diarrhea and/or Mucositis</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="75"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Associations Between MTHFR Genotypes and Grade 3-4 Diarrhea and/or Mucositis (Good Risk Group)</title>
            <description>Genomic DNA was isolated from whole blood using the Puregene DNA isolation kit.
MTHFR gene = methylenetetrahydrofolate reductase (NAD(P)H)</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>CC (MTHFR 677C&gt;T)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CT (MTHFR 677C&gt;T)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TT (MTHFR 677C&gt;T)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Associations Between MTHFR Genotypes and Grade 3-4 Diarrhea and/or Mucositis (Poor Risk Group)</title>
        <description>Genomic DNA was isolated from whole blood using the Puregene DNA isolation kit.</description>
        <time_frame>First day of treatment through 30 days after completion of surgery</time_frame>
        <safety_issue>No</safety_issue>
        <population>2 of the patients in the Poor Risk arm withdrew consent and are not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Without Grade 3-4 Diarrhea and/or Mucositis</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Irinotecan 50 mg/m2 IV weekly for 5 doses.
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
          <group group_id="O2">
            <title>With Grade 3-4 Diarrhea and/or Mucositis</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Irinotecan 50 mg/m2 IV weekly for 5 doses.
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Associations Between MTHFR Genotypes and Grade 3-4 Diarrhea and/or Mucositis (Poor Risk Group)</title>
            <description>Genomic DNA was isolated from whole blood using the Puregene DNA isolation kit.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>CC (MTHFR 677C&gt;T)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CT (MTHFR 677C&gt;T)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TT (MTHFR 677C&gt;T)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Associations Between MTHFR Genotypes and Grade 3-4 Diarrhea and/or Mucositis (Good Risk Group)</title>
        <description>Genomic DNA was isolated from whole blood using the Puregene DNA isolation kit.</description>
        <time_frame>First day of treatment through 30 days after completion of surgery</time_frame>
        <safety_issue>No</safety_issue>
        <population>2 of the patients in the Good Risk arm withdrew consent and are not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Without Grade 3-4 Diarrhea and/or Mucositis</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
          <group group_id="O2">
            <title>With Grade 3-4 Diarrhea and/or Mucositis</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="75"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Associations Between MTHFR Genotypes and Grade 3-4 Diarrhea and/or Mucositis (Good Risk Group)</title>
            <description>Genomic DNA was isolated from whole blood using the Puregene DNA isolation kit.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>AA (MTHFR 1298A&gt;C)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AC (MTHFR 1298A&gt;C)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CC (MTHFR 1298A&gt;C)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Associations Between MTHFR Genotypes and Grade 3-4 Diarrhea and/or Mucositis (Poor Risk Group)</title>
        <description>Genomic DNA was isolated from whole blood using the Puregene DNA isolation kit.</description>
        <time_frame>First day of treatment through 30 days after completion of surgery</time_frame>
        <safety_issue>No</safety_issue>
        <population>2 of the patients in the Poor Risk arm withdrew consent and are not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Without Grade 3-4 Diarrhea and/or Mucositis</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Irinotecan 50 mg/m2 IV weekly for 5 doses.
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
          <group group_id="O2">
            <title>With Grade 3-4 Diarrhea and/or Mucositis</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Irinotecan 50 mg/m2 IV weekly for 5 doses.
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Associations Between MTHFR Genotypes and Grade 3-4 Diarrhea and/or Mucositis (Poor Risk Group)</title>
            <description>Genomic DNA was isolated from whole blood using the Puregene DNA isolation kit.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>AA (MTHFR 1298A&gt;C)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AC (MTHFR 1298A&gt;C)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CC (MTHFR 1298A&gt;C)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Associations Between MTHFR Haplotypes and Grade 3-4 Diarrhea and/or Mucositis (Good Risk Group)</title>
        <description>Genomic DNA was isolated from whole blood using the Puregene DNA isolation kit.</description>
        <time_frame>First day of treatment through 30 days after completion of surgery</time_frame>
        <safety_issue>No</safety_issue>
        <population>2 of the patients in the Good Risk arm withdrew consent and are not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Without Grade 3-4 Diarrhea and/or Mucositis</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
          <group group_id="O2">
            <title>With Grade 3-4 Diarrhea and/or Mucositis</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="75"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Associations Between MTHFR Haplotypes and Grade 3-4 Diarrhea and/or Mucositis (Good Risk Group)</title>
            <description>Genomic DNA was isolated from whole blood using the Puregene DNA isolation kit.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>677C-1298A</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>677C-1298C</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>677T-1298A</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Associations Between MTHFR Haplotypes and Grade 3-4 Diarrhea and/or Mucositis (Poor Risk Group)</title>
        <description>Genomic DNA was isolated from whole blood using the Puregene DNA isolation kit.</description>
        <time_frame>First day of treatment through 30 days after completion of surgery</time_frame>
        <safety_issue>No</safety_issue>
        <population>2 of the patients in the Poor Risk arm withdrew consent and are not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Without Grade 3-4 Diarrhea and/or Mucositis</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Irinotecan 50 mg/m2 IV weekly for 5 doses.
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
          <group group_id="O2">
            <title>With Grade 3-4 Diarrhea and/or Mucositis</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Irinotecan 50 mg/m2 IV weekly for 5 doses.
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Associations Between MTHFR Haplotypes and Grade 3-4 Diarrhea and/or Mucositis (Poor Risk Group)</title>
            <description>Genomic DNA was isolated from whole blood using the Puregene DNA isolation kit.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>677C-1298A</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>677C-1298C</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>677T-1298A</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Associations Between MTHFR Diplotypes and Grade 3-4 Diarrhea and/or Mucositis (Good Risk Group)</title>
        <description>Genomic DNA was isolated from whole blood using the Puregene DNA isolation kit.</description>
        <time_frame>First day of treatment through 30 days after completion of surgery</time_frame>
        <safety_issue>No</safety_issue>
        <population>2 of the patients in the Good Risk arm withdrew consent and are not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Without Grade 3-4 Diarrhea and/or Mucositis</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
          <group group_id="O2">
            <title>With Grade 3-4 Diarrhea and/or Mucositis</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="75"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Associations Between MTHFR Diplotypes and Grade 3-4 Diarrhea and/or Mucositis (Good Risk Group)</title>
            <description>Genomic DNA was isolated from whole blood using the Puregene DNA isolation kit.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>CA-CA</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CA-CC</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CA-TA</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CC-CC</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CC-TA</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CC-TC</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TA-TA</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Associations Between MTHFR Diplotypes and Grade 3-4 Diarrhea and/or Mucositis (Poor Risk Group)</title>
        <description>Genomic DNA was isolated from whole blood using the Puregene DNA isolation kit.</description>
        <time_frame>First day of treatment through 30 days after completion of surgery</time_frame>
        <safety_issue>No</safety_issue>
        <population>2 of the patients in the Poor Risk arm withdrew consent and are not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Without Grade 3-4 Diarrhea and/or Mucositis</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Irinotecan 50 mg/m2 IV weekly for 5 doses.
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
          <group group_id="O2">
            <title>With Grade 3-4 Diarrhea and/or Mucositis</title>
            <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Irinotecan 50 mg/m2 IV weekly for 5 doses.
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Associations Between MTHFR Diplotypes and Grade 3-4 Diarrhea and/or Mucositis (Poor Risk Group)</title>
            <description>Genomic DNA was isolated from whole blood using the Puregene DNA isolation kit.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>CA-CA</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CA-CC</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CA-TA</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CC-CC</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CC-TA</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CC-TC</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>TA-TA</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Beginning of treatment through 30 days after the end of surgery.</time_frame>
      <desc>Two patients in both the &quot;Good Risk Arm&quot; and the &quot;Poor Risk Arm&quot; withdrew consent and are not included.</desc>
      <group_list>
        <group group_id="E1">
          <title>Good Risk (Thymidylate Synthase (TYMS)*2/*2, *2/*3, *2/*4)</title>
          <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
        </group>
        <group group_id="E2">
          <title>Poor Risk (Thymidylate Synthase (TYMS)*3/*3, *3/*4)</title>
          <description>Radiation 45 Gy in 25 fractions to the pelvis.
5FU CIVI 225 mg/m2/day by CIVI during radiation
Irinotecan 50 mg/m2 IV weekly for 5 doses.
Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Anemia-blood transfusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Aneurysmal bleed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea/RT enteritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Perforation/abscess/leak fistula</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bleed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Crohn's flare</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE 2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE (2.0)">Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/vision-eye discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE (2.0)">Nausea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Constipation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Indigestion/cramping</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Tenesmus</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Rectal spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Flatus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Stomatitis/mucositis</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Ileitis/Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Bleeding-GI</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pain-rectum</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Fever without infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE (2.0)">Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Platelets</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Bilirubin - increased</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">SGOT/SGPT - increased</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Alkaline phosphatase - increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">BUN - increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Creatinine -increased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Sweats</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PT</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PTT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Defibrillator malfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE (2.0)">Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypoprotenemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy - motor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Tremors</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pain-head, headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration-depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Mood alteration-anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE (2.0)">Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE (2.0)">Hiccoughs</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin itching/irritation/rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Skin dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Erythema/PPE</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hand-foot syndrome</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE (2.0)">Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="CTCAE (2.0)">Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Benjamin R. Tan, M.D.</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-362-3560</phone>
      <email>btan@dom.wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
